MIANSERINE VIATRIS 10 mg Coated Tablet Bottle/30

Film-coated tablet.

Mianserin hydrochloride.........................................................................................................................10 mg

For a film-coated tablet.

Excipients:

• Major depressive episodes (i.e. characterised).

Dosage

The dosage is to be adapted to each case and may vary between 30 mg and 90 mg per day.

Adults : Treatment will begin with 3 tablets per day.

In some patients, depending on their individual sensitivity, the dosage will be introduced gradually (over one week).

Elderly patients : In elderly subjects, it is recommended to reduce the dosage; half the average dosage may be sufficient.

Paediatric population (children and adolescents under 18 years) : The tolerability and efficacy of mianserin have not been established in children. Mianserin is not recommended in children and adolescents under 18 years (see section Warnings and precautions).

Method of administration

Tablets to be swallowed without chewing.

The daily dose may either be divided over the day, or preferably administered in the evening at bedtime (in which case a single dose should not exceed 60 mg).

Duration of treatment

Antidepressant treatment is symptomatic.

Treatment of an episode lasts several months (usually of the order of 6 months) in order to prevent the risk of relapse of the depressive episode.

This medicine must NEVER be used in the following cases:

• hypersensitivity to the active substance or to any of the excipients listed in section Composition ;

• severe hepatic impairment;

• due to the increased serious risk of ventricular rhythm disorders, in particular torsades de pointes, the use of mianserin is contraindicated with another medicinal product likely to prolong the QT interval, such as for example amiodarone, citalopram, disopyramide, domperidone, dronedarone, erythromycin, escitalopram, hydroquinidine, hydroxyzine, mequitazine, moxifloxacin, quinidine, sotalol, spiramycin IV and oral route.

Special warnings

Suicides/suicidal ideation or clinical worsening

Depression is associated with an increased risk of suicidal ideation, self-harm and suicide (suicide-related behaviour). This risk persists until significant remission is achieved. As clinical improvement may not occur before several weeks of treatment, patients should be closely monitored until such improvement is achieved. Clinical experience shows that suicidal risk may increase at the very beginning of recovery.

Patients with a history of suicide-related behaviour or those expressing significant suicidal ideation before starting treatment are at higher risk of suicidal thoughts or suicide-related behaviour and must be closely monitored during treatment. A meta-analysis of placebo-controlled clinical trials on the use of antidepressants in adults with psychiatric disorders showed an increased risk of suicide-related behaviour in patients under 25 years of age treated with antidepressants compared with those receiving placebo. Close monitoring of patients, particularly those at high risk, must accompany drug treatment, especially at the start of treatment and when doses are changed. Patients (and their carers) must be advised to watch for the occurrence of clinical worsening, emergence of suicidal thoughts/behaviours and any unusual changes in behaviour, and to seek medical advice immediately if such symptoms occur.

In view of the suicide risk, particularly at the beginning of treatment, the smallest dispensable quantity of MIANSERINE VIATRIS film-coated tablets, compatible with proper patient management, should be prescribed to the patient.

QT interval prolongation / ventricular tachycardia

Cases of QT interval prolongation and ventricular tachycardia have been reported since the marketing of mianserin. The majority of cases occurred in the context of overdose or in patients presenting other risk factors for prolongation of the QTc interval, including concomitant use of medicinal products that prolong the QTc interval (see sections Interactions and Overdose). Caution is recommended when mianserin is prescribed to patients with known cardiovascular disease or a family history of QTc interval prolongation, in cases of hypokalaemia, as well as in combination with other medicinal products likely to prolong the QTc interval.

Use in children and adolescents under 18 years

The use of MIANSERINE VIATRIS is not recommended in children and adolescents under 18 years of age. Suicide-related behaviours (suicide attempts and suicidal ideation) and hostility-related behaviours (mainly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials in children and adolescents treated with antidepressants compared with those treated with placebo. If, in case of clinical need, the decision to treat is nevertheless taken, the patient should be carefully monitored for the emergence of suicidal symptoms. In addition, no long-term safety data are available in children and adolescents concerning growth, maturation and cognitive and behavioural development.

Agranulocytosis

Exceptional cases of agranulocytosis have been reported, particularly in elderly persons over 65 years of age. Monitoring of the blood count is therefore recommended, particularly when the patient presents with fever, sore throat or other signs of infection.

Precautions for use

Insomnia or nervousness at the beginning of treatment may justify transitory symptomatic treatment.

In epileptic patients or patients with a history of epilepsy, it is prudent to reinforce clinical and electroencephalographic monitoring, due to the possibility of lowering of the epileptogenic threshold. The occurrence of convulsive seizures requires discontinuation of treatment.

Mianserin should be used with caution in patients with unstabilised diabetes: monitor blood glucose.

Combinations not recommended

Alcohol

Alcohol increases the sedative effect of these substances. Impaired alertness may make driving vehicles and using machines dangerous.

Avoid taking alcoholic beverages and medicines containing alcohol.

CYP3A4 inducing antiepileptics

Concomitant administration of CYP3A4 inducing antiepileptic medicinal products (such as phenytoin and carbamazepine) may decrease plasma levels of mianserin. A dose adjustment should be considered when combination with these medicinal products is initiated or discontinued.

Medicinal products likely to prolong the QT interval

Due to a delicate therapeutic substitution with certain medicinal products likely to prolong the QT interval, combination with the following medicinal products is not recommended:

• certain antiparasitic medicinal products likely to cause torsades de pointes (such as for example chloroquine, halofantrine, lumefantrine, pentamidine, hydroxychloroquine);

• certain neuroleptic medicinal products likely to cause torsades de pointes (such as for example chlorpromazine, haloperidol, pimozide,…);

• arsenic trioxide;

• methadone;

• crizotinib;

• or co-trimoxazole.

Associations requiring precautions for use

As hypokalaemia and bradycardia are factors that may increase the occurrence of cardiac rhythm disorders, combination of hypokalaemia-inducing medicinal products (such as for example betamethasone, clopamide, cortisone, dexamethasone, furosemide, hydrochlorothiazide,…) or bradycardia-inducing medicinal products (such as for example atenolol, betaxolol, bisoprolol, crizotinib, digoxin, diltiazem, thalidomide, verapamil,…) requires precautions for use, including clinical and electrocardiographic monitoring during combination.

Associations to be taken into account

Other central nervous system depressants: morphine derivatives (analgesics, antitussives and substitution treatments); barbiturates; benzodiazepines; anxiolytics other than benzodiazepines: carbamates, captodiame, etifoxine; hypnotics; neuroleptics; sedating H1 antihistamines; centrally acting antihypertensives; baclofen; thalidomide.

Increased central depression. Impaired alertness may make driving vehicles and using machines dangerous.

Pregnancy

Maintaining good maternal psychological balance is desirable throughout pregnancy. If drug treatment is necessary to ensure this balance, it should be instituted or continued at an effective dose throughout pregnancy and, if possible, as monotherapy.

Animal data are reassuring but clinical data are still insufficient.

In view of these data, it is preferable to avoid mianserin during pregnancy, whatever the term. If it proves essential to initiate or maintain treatment with mianserin during pregnancy, take into account the pharmacological profile of the molecule when monitoring the newborn.

Breast-feeding

Due to the low passage of mianserin into breast milk, breastfeeding is not recommended for the duration of treatment.

Attention is drawn, particularly to vehicle drivers and machine operators, to the risks of drowsiness associated with the use of this medicinal product.

The adverse effects in the table below were collected during clinical trials with MIANSERINE VIATRIS and since its marketing. Adverse effects are classified by system organ class, applying the following conventions: 

• very common (≥ 1/10),

• common (≥ 1/100, < 1/10),

• uncommon (≥ 1/1 000, < 1/100),

• rare (≥ 1/10 000, < 1/1 000),

• very rare (< 1/10 000),

• frequency not known (cannot be estimated from the available data).

The adverse effects most frequently reported with MIANSERINE VIATRIS are weight gain, somnolence, elevated liver enzymes and oedema.

System Organ Classes
Cardiac disorders
Frequency not known	Bradycardia
	QTc interval prolongation and ventricular tachycardia
Blood and lymphatic system disorders
Frequency not known	Agranulocytosis (see section Warnings and precautions)
Skin and subcutaneous tissue disorders
Frequency not known	Exanthema
Nervous system disorders
Very common	Somnolence
Frequency not known	Convulsions
	Hyperkinesia
Gastrointestinal disorders
Frequency not known	Constipation
	Dry mouth
Hepatobiliary disorders
Frequency not known	Increased liver enzymes
	Abnormal liver function
	Jaundice
	Hepatitis
Musculoskeletal and systemic disorders
Frequency not known	Arthralgia and myalgia
Vascular disorders
Frequency not known	Hypotension
Metabolism and nutrition disorders
Very common	Weight gain
General disorders and administration site conditions
Frequency not known	Oedema

• Certain undesirable effects may be related to the nature of the depressive illness itself:

• lifting of psychomotor inhibition, with suicidal risk;
• mood inversion with onset of manic episodes;
•  reactivation of delusions in psychotic subjects;
•  paroxysmal manifestations of anxiety (for psychostimulant antidepressants).

Cases of suicidal ideation and behaviour have been reported during treatment with MIANSERINE VIATRIS or shortly after its discontinuation (see section Warnings and precautions).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr/

An overdose generally causes drowsiness. Cases of prolongation of the QTc interval have been reported in cases of mianserin overdose.

There is no specific antidote for mianserin.

Treatment in case of overdose consists of rapid evacuation of gastric contents, correction of fluid and electrolyte disorders and maintenance of vital functions until the product is eliminated. This elimination is not enhanced by haemodialysis.

Pharmacotherapeutic class: other antidepressants, ATC code: N06AX03 (N: nervous system).

Mianserin, the active substance of MIANSERINE VIATRIS, is an antidepressant distinct from tricyclic antidepressants.

Its properties and side effects are different: it increases the release of central noradrenaline through a presynaptic α2 antagonist effect. It inhibits noradrenaline reuptake to a lesser extent. In addition, interactions with central serotonergic and antihistaminic receptors have been described.

Studies in humans have shown that mianserin, in addition to its antidepressant properties, has an anxiolytic and sedative action and a sleep-regulating effect.

They have also shown the absence of anticholinergic and cardiovascular effects of mianserin at therapeutic doses.

Mianserin is rapidly absorbed by the digestive route. The maximum plasma concentration is obtained in 2 to 3 hours and steady state in approximately 6 days. The mean elimination half-life is close to 40 hours, and may vary between 21 and 61 hours.

Bioavailability is approximately 20 %. Mianserin is bound at 95 % to plasma proteins, and this binding is not modified by the concomitant administration of antidepressants, neuroleptics or anxiolytics.

The major pathways of biotransformation are demethylation and oxidation, followed by conjugation. These metabolites are excreted (on average at 70 %) in the urine and the remainder in the feces (up to 30 %).

2 years.

After first opening of the bottle : to be kept 30 days.

Store below 25°C and protected from light.

No special requirements.

List I

Marketing authorisation (AMM)

CIP 3400933423797 (Plq/30). CIP 3400930043738 (Fl/30).

Price:

2,15 euros (Blister/30). 2,15 euros (Fl/30).

Social Security reimbursement at 65% (Plq/30).
Social Security reimbursement at 65% (Fl/30) in the indications:

• Indication(s) listed in the marketing authorization on the date of publication of this order (Fl/30)

Collection.